7 March 2023 Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline read more
5 January 2023 Affini-T Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference read more
22 September 2022 The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies read more
14 September 2022 Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering read more
12 September 2022 Scorpion Therapeutics, Volastra Therapeutics and ReCode Therapeutics Selected in Fierce Biotech’s 2022 Fierce 15 read more
